Imbria Pharmaceuticals is a clinical-stage company focused on improving cardiac energetics to treat serious cardiovascular diseases. Its lead candidate, ninerafaxstat, is designed to enhance cardiac energy production without affecting heart rate, rhythm, ejection fraction, or blood pressure. The drug is currently being evaluated in FORTITUDE-HCM, a global Phase 2b trial for symptomatic non-obstructive hypertrophic cardiomyopathy, a condition with no approved treatments. The company’s strategy centers on positioning ninerafaxstat as a first-in-class therapy with broad cardiovascular applications. Recent Series B proceeds will fund continued clinical development and trial execution. The financing also expands Imbria’s board, adding representatives from new and existing investors, which may deepen strategic guidance and industry connections. Although the round size remains undisclosed, the expanded investor syndicate signals confidence in the company’s progress and future potential.

Total raised

$58M

Funding rounds

2

Latest round

Series B

Latest activity

Apr 2025